This brand name is authorized in Spain, United Kingdom
The drug GHRH contains one active pharmaceutical ingredient (API):
|
1
Somatorelin
UNII XY920R6F5N - SOMATORELIN ACETATE
|
|
Somatorelin is normally synthesised in the hypothalamus and stimulates the secretion of growth hormone from the pituitary gland. Somatorelin physiologically increases plasma growth hormone levels. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| GHRH Lyophilised powder for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V04CD05 | Somatorelin | V Various → V04 Diagnostic agents → V04C Other diagnostic agents → V04CD Tests for pituitary function |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 59109 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 48503 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
